[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$feiVUnTR0rc4_zjeuxRihwH4eJwKXTMtXWLmsf4oCKuU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Meshalkin Research Institute of Pathology of Circulation",[4],118,false,6,19,25344,2,85,[14,16,19,22,24,26,29,31],{"name":15,"count":9},"Atrial Fibrillation",{"name":17,"count":18},"Coronary Artery Disease",13,{"name":20,"count":21},"Ischemic Heart Disease",7,{"name":23,"count":8},"Cardiac Surgery",{"name":25,"count":8},"Paroxysmal Atrial Fibrillation",{"name":27,"count":28},"Hypertrophic Obstructive Cardiomyopathy",4,{"name":30,"count":28},"Coronary Atherosclerosis",{"name":32,"count":28},"Coronary Artery Stenosis",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07434661","Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR","2028-01","Apixaban",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,123,154,193,211,229,255,273,291,316,343,361,425,458,495,527,545,563,581,599,617,635,653,678,703,729,747,773,791,809,838,856,874,896,919,937,962,985,1003,1021,1047,1071],{"intervention":48,"totalTrials":49,"cells":50},"Warfarin",5,{"EARLY_PHASE1":51,"PHASE1":54,"PHASE2":56,"PHASE3":91,"PHASE4":109,"NA":121},{"trials":52,"activeCount":53},[],0,{"trials":55,"activeCount":53},[],{"trials":57,"activeCount":53},[58,71,81],{"nctId":59,"briefTitle":60,"status":61,"phases":62,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":69},"NCT02238535","Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension","UNKNOWN",[42],"2016-03","2016-10","2014-09",60,[68],"Residual Pulmonary Hypertension",[70,48],"Ventavis",{"nctId":72,"briefTitle":73,"status":74,"phases":75,"primaryCompletion":76,"completion":76,"start":77,"enrollment":78,"conditions":79,"interventions":80},"NCT01695824","Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation","COMPLETED",[42],"2014-11","2011-12",96,[15],[48],{"nctId":82,"briefTitle":83,"status":61,"phases":84,"primaryCompletion":63,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":90},"NCT02492230","Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI",[42],"2017-12","2015-05",50,[89],"Myocardial Infarction",[48],{"trials":92,"activeCount":108,"soonestReadout":37},[93],{"nctId":35,"briefTitle":36,"status":94,"phases":95,"primaryCompletion":37,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":107},"NOT_YET_RECRUITING",[43],"2029-01","2026-02",120,[100,101,102,103,104,105,106],"Valve Disease, Heart","Atrial Fibrillation (AF)","Valve Replacement Surgery","Aortic Valve Surgery","Mitral Valve Annuloplasty","Mitral Valve Repair","Mitral Valve Surgery",[38,48],1,{"trials":110,"activeCount":53},[111],{"nctId":112,"briefTitle":113,"status":61,"phases":114,"primaryCompletion":115,"completion":115,"start":64,"enrollment":116,"conditions":117,"interventions":119},"NCT02979561","Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy",[44],"2018-06",200,[118],"Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy",[120,48],"Dabigatran Etexilate",{"trials":122,"activeCount":53},[],{"intervention":124,"totalTrials":11,"cells":125},"apixaban",{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":142,"PHASE3":144,"PHASE4":150,"NA":152},{"trials":127,"activeCount":53},[],{"trials":129,"activeCount":53},[130],{"nctId":131,"briefTitle":132,"status":61,"phases":133,"primaryCompletion":134,"completion":134,"start":64,"enrollment":135,"conditions":136,"interventions":140},"NCT02946944","Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism",[41],"2020-10",100,[137,138,139],"Pulmonary Embolism","Intermediate-high Risk","Combination of Oral Anticoagulation Therapy and Sildenafil",[141,124],"Sildenafil\u002Fapixaban",{"trials":143,"activeCount":53},[],{"trials":145,"activeCount":108,"soonestReadout":37},[146],{"nctId":35,"briefTitle":36,"status":94,"phases":147,"primaryCompletion":37,"completion":96,"start":97,"enrollment":98,"conditions":148,"interventions":149},[43],[100,101,102,103,104,105,106],[38,48],{"trials":151,"activeCount":53},[],{"trials":153,"activeCount":53},[],{"intervention":155,"totalTrials":11,"cells":156},"Propofol",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":191},{"trials":158,"activeCount":53},[],{"trials":160,"activeCount":53},[],{"trials":162,"activeCount":53},[],{"trials":164,"activeCount":53},[],{"trials":166,"activeCount":53},[167,178],{"nctId":168,"briefTitle":169,"status":74,"phases":170,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"NCT03729011","Delirium Reduction by Volatile Anesthesia in Cardiac Surgery",[44],"2024-01-11","2019-01-09",405,[175],"Delirium",[177,155],"Volatile agent",{"nctId":179,"briefTitle":180,"status":74,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":189},"NCT03514550","Effects of Anesthesia on Immunity in Cancer",[44],"2019-04-01","2019-05-20","2018-05-14",20,[187,188],"Surgery","Renal Cancer",[155,190],"Sevoflurane",{"trials":192,"activeCount":53},[],{"intervention":177,"totalTrials":108,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":209},{"trials":196,"activeCount":53},[],{"trials":198,"activeCount":53},[],{"trials":200,"activeCount":53},[],{"trials":202,"activeCount":53},[],{"trials":204,"activeCount":53},[205],{"nctId":168,"briefTitle":169,"status":74,"phases":206,"primaryCompletion":171,"completion":171,"start":172,"enrollment":173,"conditions":207,"interventions":208},[44],[175],[177,155],{"trials":210,"activeCount":53},[],{"intervention":120,"totalTrials":108,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":227},{"trials":214,"activeCount":53},[],{"trials":216,"activeCount":53},[],{"trials":218,"activeCount":53},[],{"trials":220,"activeCount":53},[],{"trials":222,"activeCount":53},[223],{"nctId":112,"briefTitle":113,"status":61,"phases":224,"primaryCompletion":115,"completion":115,"start":64,"enrollment":116,"conditions":225,"interventions":226},[44],[118],[120,48],{"trials":228,"activeCount":53},[],{"intervention":230,"totalTrials":108,"cells":231},"Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":253},{"trials":233,"activeCount":53},[],{"trials":235,"activeCount":53},[],{"trials":237,"activeCount":53},[],{"trials":239,"activeCount":53},[],{"trials":241,"activeCount":53},[242],{"nctId":243,"briefTitle":244,"status":74,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":251},"NCT03306732","Thiamine Supplementation in High Risk Cardiac Surgery Patients",[44],"2018-05-18","2018-06-18","2017-10-19",40,[23],[230,252],"Normal saline",{"trials":254,"activeCount":53},[],{"intervention":252,"totalTrials":108,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":265,"NA":271},{"trials":258,"activeCount":53},[],{"trials":260,"activeCount":53},[],{"trials":262,"activeCount":53},[],{"trials":264,"activeCount":53},[],{"trials":266,"activeCount":53},[267],{"nctId":243,"briefTitle":244,"status":74,"phases":268,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":269,"interventions":270},[44],[23],[230,252],{"trials":272,"activeCount":53},[],{"intervention":190,"totalTrials":108,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":281,"PHASE4":283,"NA":289},{"trials":276,"activeCount":53},[],{"trials":278,"activeCount":53},[],{"trials":280,"activeCount":53},[],{"trials":282,"activeCount":53},[],{"trials":284,"activeCount":53},[285],{"nctId":179,"briefTitle":180,"status":74,"phases":286,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":287,"interventions":288},[44],[187,188],[155,190],{"trials":290,"activeCount":53},[],{"intervention":292,"totalTrials":108,"cells":293},"Esmolol",{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":314},{"trials":295,"activeCount":53},[],{"trials":297,"activeCount":53},[],{"trials":299,"activeCount":53},[],{"trials":301,"activeCount":53},[],{"trials":303,"activeCount":53},[304],{"nctId":305,"briefTitle":306,"status":61,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":313},"NCT05073094","Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy",[44],"2023-06-01","2023-07-01","2021-10-06",80,[27],[292],{"trials":315,"activeCount":53},[],{"intervention":317,"totalTrials":108,"cells":318},"Calcium Chloride",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":327,"NA":341},{"trials":320,"activeCount":53},[],{"trials":322,"activeCount":53},[],{"trials":324,"activeCount":53},[],{"trials":326,"activeCount":53},[],{"trials":328,"activeCount":53},[329],{"nctId":330,"briefTitle":331,"status":74,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT03772990","Calcium Administration in Cardiac Surgery",[44],"2025-07-13","2025-08-13","2019-01-14",818,[23,338],"Cardiopulmonary Bypass",[317,340],"0.9% Sodium Chloride",{"trials":342,"activeCount":53},[],{"intervention":340,"totalTrials":108,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":359},{"trials":346,"activeCount":53},[],{"trials":348,"activeCount":53},[],{"trials":350,"activeCount":53},[],{"trials":352,"activeCount":53},[],{"trials":354,"activeCount":53},[355],{"nctId":330,"briefTitle":331,"status":74,"phases":356,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":357,"interventions":358},[44],[23,338],[317,340],{"trials":360,"activeCount":53},[],{"intervention":362,"totalTrials":49,"cells":363},"botulinum toxin",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":380,"PHASE3":410,"PHASE4":421,"NA":423},{"trials":365,"activeCount":53},[],{"trials":367,"activeCount":53},[368],{"nctId":369,"briefTitle":370,"status":61,"phases":371,"primaryCompletion":63,"completion":372,"start":373,"enrollment":374,"conditions":375,"interventions":378},"NCT02003001","Botulinum Toxin Injection to Prevent Ventricular Arrhythmias",[41],"2016-12","2013-06",30,[376,377],"Symptomatic Ventricular Asystolia","Ventricular Tachycardia",[379],"Botulinum Toxin",{"trials":381,"activeCount":53},[382,391,401],{"nctId":383,"briefTitle":384,"status":61,"phases":385,"primaryCompletion":386,"completion":387,"start":373,"enrollment":66,"conditions":388,"interventions":390},"NCT02008461","Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias",[42],"2015-12","2016-02",[389],"Supra-ventricular Tachyarrhythmias",[362],{"nctId":392,"briefTitle":393,"status":74,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":66,"conditions":397,"interventions":399},"NCT01842529","Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery",[42],"2013-12","2012-09",[25,398],"Indications for CABG",[362,400],"0.9% normal saline",{"nctId":402,"briefTitle":403,"status":61,"phases":404,"primaryCompletion":405,"completion":386,"start":373,"enrollment":406,"conditions":407,"interventions":409},"NCT02002923","Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation",[42],"2015-06",160,[25,408],"Persistent Atrial Fibrillation",[379],{"trials":411,"activeCount":53},[412],{"nctId":413,"briefTitle":414,"status":61,"phases":415,"primaryCompletion":63,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":420},"NCT02617069","Botulinum Toxin Injection Into Epicardial Fat Pads to Prevent Atrial Fibrillation in Patients Undergoing Cardiac Surgery",[42,43],"2018-03","2015-09",170,[15],[362,400],{"trials":422,"activeCount":53},[],{"trials":424,"activeCount":53},[],{"intervention":400,"totalTrials":426,"cells":427},3,{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":448,"PHASE4":454,"NA":456},{"trials":429,"activeCount":53},[],{"trials":431,"activeCount":53},[],{"trials":433,"activeCount":53},[434,438],{"nctId":392,"briefTitle":393,"status":74,"phases":435,"primaryCompletion":395,"completion":395,"start":396,"enrollment":66,"conditions":436,"interventions":437},[42],[25,398],[362,400],{"nctId":439,"briefTitle":440,"status":61,"phases":441,"primaryCompletion":85,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":446},"NCT02982434","The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation",[42],"2018-02","2016-09",180,[15,20],[447,400],"Pharmaceutical composition containing botulinum toxin",{"trials":449,"activeCount":53},[450],{"nctId":413,"briefTitle":414,"status":61,"phases":451,"primaryCompletion":63,"completion":416,"start":417,"enrollment":418,"conditions":452,"interventions":453},[42,43],[15],[362,400],{"trials":455,"activeCount":53},[],{"trials":457,"activeCount":53},[],{"intervention":459,"totalTrials":11,"cells":460},"Metoprolol",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":477,"PHASE4":491,"NA":493},{"trials":462,"activeCount":53},[],{"trials":464,"activeCount":53},[],{"trials":466,"activeCount":53},[467],{"nctId":468,"briefTitle":469,"status":61,"phases":470,"primaryCompletion":405,"completion":471,"start":373,"enrollment":311,"conditions":472,"interventions":475},"NCT01901549","Renal Denervation in Patients After Acute Coronary Syndrome",[42],"2016-06",[473,474],"Acute Coronary Syndrome","Arterial Hypertension",[459,476],"Lisinopril",{"trials":478,"activeCount":53},[479],{"nctId":480,"briefTitle":481,"status":61,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":489},"NCT02772354","Radiofrequency Ablation of Symptomatic Frequent Ventricular Premature Complexes in Pediatric Population",[42,43],"2017-09","2018-04","2016-04",124,[488],"Ventricular Arrhythmia",[459,490],"Verapamil",{"trials":492,"activeCount":53},[],{"trials":494,"activeCount":53},[],{"intervention":496,"totalTrials":108,"cells":497},"Phosphocreatine sodium tetrahydrate after anaesthesia induction",{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":523,"NA":525},{"trials":499,"activeCount":53},[],{"trials":501,"activeCount":53},[],{"trials":503,"activeCount":53},[],{"trials":505,"activeCount":53},[506],{"nctId":507,"briefTitle":508,"status":74,"phases":509,"primaryCompletion":510,"completion":511,"start":471,"enrollment":98,"conditions":512,"interventions":515},"NCT02757443","Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients",[43],"2021-04","2021-05",[513,514],"Cardiac Surgical Procedures","Heart Valve Prosthesis Implantation",[496,516,517,518,519,520,521,522],"5% Glucose after anaesthesia induction","Phosphocreatine sodium tetrahydrate added to cardioplegia","5% Glucose","Phosphocreatine sodium tetrahydrate after heart recovery","5% Glucose after heart recovery","Phosphocreatine sodium tetrahydrate after ICU admission","5% Glucose after ICU admission",{"trials":524,"activeCount":53},[],{"trials":526,"activeCount":53},[],{"intervention":516,"totalTrials":108,"cells":528},{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":541,"NA":543},{"trials":530,"activeCount":53},[],{"trials":532,"activeCount":53},[],{"trials":534,"activeCount":53},[],{"trials":536,"activeCount":53},[537],{"nctId":507,"briefTitle":508,"status":74,"phases":538,"primaryCompletion":510,"completion":511,"start":471,"enrollment":98,"conditions":539,"interventions":540},[43],[513,514],[496,516,517,518,519,520,521,522],{"trials":542,"activeCount":53},[],{"trials":544,"activeCount":53},[],{"intervention":517,"totalTrials":108,"cells":546},{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":559,"NA":561},{"trials":548,"activeCount":53},[],{"trials":550,"activeCount":53},[],{"trials":552,"activeCount":53},[],{"trials":554,"activeCount":53},[555],{"nctId":507,"briefTitle":508,"status":74,"phases":556,"primaryCompletion":510,"completion":511,"start":471,"enrollment":98,"conditions":557,"interventions":558},[43],[513,514],[496,516,517,518,519,520,521,522],{"trials":560,"activeCount":53},[],{"trials":562,"activeCount":53},[],{"intervention":518,"totalTrials":108,"cells":564},{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":577,"NA":579},{"trials":566,"activeCount":53},[],{"trials":568,"activeCount":53},[],{"trials":570,"activeCount":53},[],{"trials":572,"activeCount":53},[573],{"nctId":507,"briefTitle":508,"status":74,"phases":574,"primaryCompletion":510,"completion":511,"start":471,"enrollment":98,"conditions":575,"interventions":576},[43],[513,514],[496,516,517,518,519,520,521,522],{"trials":578,"activeCount":53},[],{"trials":580,"activeCount":53},[],{"intervention":519,"totalTrials":108,"cells":582},{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":595,"NA":597},{"trials":584,"activeCount":53},[],{"trials":586,"activeCount":53},[],{"trials":588,"activeCount":53},[],{"trials":590,"activeCount":53},[591],{"nctId":507,"briefTitle":508,"status":74,"phases":592,"primaryCompletion":510,"completion":511,"start":471,"enrollment":98,"conditions":593,"interventions":594},[43],[513,514],[496,516,517,518,519,520,521,522],{"trials":596,"activeCount":53},[],{"trials":598,"activeCount":53},[],{"intervention":520,"totalTrials":108,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":613,"NA":615},{"trials":602,"activeCount":53},[],{"trials":604,"activeCount":53},[],{"trials":606,"activeCount":53},[],{"trials":608,"activeCount":53},[609],{"nctId":507,"briefTitle":508,"status":74,"phases":610,"primaryCompletion":510,"completion":511,"start":471,"enrollment":98,"conditions":611,"interventions":612},[43],[513,514],[496,516,517,518,519,520,521,522],{"trials":614,"activeCount":53},[],{"trials":616,"activeCount":53},[],{"intervention":521,"totalTrials":108,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":631,"NA":633},{"trials":620,"activeCount":53},[],{"trials":622,"activeCount":53},[],{"trials":624,"activeCount":53},[],{"trials":626,"activeCount":53},[627],{"nctId":507,"briefTitle":508,"status":74,"phases":628,"primaryCompletion":510,"completion":511,"start":471,"enrollment":98,"conditions":629,"interventions":630},[43],[513,514],[496,516,517,518,519,520,521,522],{"trials":632,"activeCount":53},[],{"trials":634,"activeCount":53},[],{"intervention":522,"totalTrials":108,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":649,"NA":651},{"trials":638,"activeCount":53},[],{"trials":640,"activeCount":53},[],{"trials":642,"activeCount":53},[],{"trials":644,"activeCount":53},[645],{"nctId":507,"briefTitle":508,"status":74,"phases":646,"primaryCompletion":510,"completion":511,"start":471,"enrollment":98,"conditions":647,"interventions":648},[43],[513,514],[496,516,517,518,519,520,521,522],{"trials":650,"activeCount":53},[],{"trials":652,"activeCount":53},[],{"intervention":654,"totalTrials":108,"cells":655},"N(2)-L-Alanine L-Glutamine dipeptide",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":674,"NA":676},{"trials":657,"activeCount":53},[],{"trials":659,"activeCount":53},[],{"trials":661,"activeCount":53},[],{"trials":663,"activeCount":53},[664],{"nctId":665,"briefTitle":666,"status":74,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":673},"NCT01478126","Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass",[43],"2012-12","2013-09","2012-01",24,[17],[654],{"trials":675,"activeCount":53},[],{"trials":677,"activeCount":53},[],{"intervention":679,"totalTrials":108,"cells":680},"Dexamethasone",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":699,"NA":701},{"trials":682,"activeCount":53},[],{"trials":684,"activeCount":53},[],{"trials":686,"activeCount":53},[],{"trials":688,"activeCount":53},[689],{"nctId":690,"briefTitle":691,"status":74,"phases":692,"primaryCompletion":693,"completion":694,"start":386,"enrollment":695,"conditions":696,"interventions":698},"NCT02615262","Intraoperative Dexamethasone in Pediatric Cardiac Surgery",[43],"2018-11","2018-12",394,[23,697,338],"Congenital Heart Defects",[679],{"trials":700,"activeCount":53},[],{"trials":702,"activeCount":53},[],{"intervention":704,"totalTrials":108,"cells":705},"acetylsalicylic acid started for 24 hours before surgery",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":725,"NA":727},{"trials":707,"activeCount":53},[],{"trials":709,"activeCount":53},[],{"trials":711,"activeCount":53},[],{"trials":713,"activeCount":53},[714],{"nctId":715,"briefTitle":716,"status":61,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":723},"NCT02942680","Efficacy and Safety of Aspirin Therapy With CABG",[43],"2018-01","2016-01",350,[722],"Coronary Heart Disease",[704,724],"acetylsalicylic acid stayed for 5 days before surgery",{"trials":726,"activeCount":53},[],{"trials":728,"activeCount":53},[],{"intervention":724,"totalTrials":108,"cells":730},{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":743,"NA":745},{"trials":732,"activeCount":53},[],{"trials":734,"activeCount":53},[],{"trials":736,"activeCount":53},[],{"trials":738,"activeCount":53},[739],{"nctId":715,"briefTitle":716,"status":61,"phases":740,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":741,"interventions":742},[43],[722],[704,724],{"trials":744,"activeCount":53},[],{"trials":746,"activeCount":53},[],{"intervention":748,"totalTrials":108,"cells":749},"Omega-3 fish oil emulsion",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":769,"NA":771},{"trials":751,"activeCount":53},[],{"trials":753,"activeCount":53},[],{"trials":755,"activeCount":53},[],{"trials":757,"activeCount":53},[758],{"nctId":759,"briefTitle":760,"status":761,"phases":762,"primaryCompletion":668,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":767},"NCT01175330","Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting","TERMINATED",[43],"2013-08","2010-08",39,[20,15],[748,768],"Intralipid",{"trials":770,"activeCount":53},[],{"trials":772,"activeCount":53},[],{"intervention":768,"totalTrials":108,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":787,"NA":789},{"trials":776,"activeCount":53},[],{"trials":778,"activeCount":53},[],{"trials":780,"activeCount":53},[],{"trials":782,"activeCount":53},[783],{"nctId":759,"briefTitle":760,"status":761,"phases":784,"primaryCompletion":668,"completion":763,"start":764,"enrollment":765,"conditions":785,"interventions":786},[43],[20,15],[748,768],{"trials":788,"activeCount":53},[],{"trials":790,"activeCount":53},[],{"intervention":490,"totalTrials":108,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":799,"PHASE4":805,"NA":807},{"trials":794,"activeCount":53},[],{"trials":796,"activeCount":53},[],{"trials":798,"activeCount":53},[],{"trials":800,"activeCount":53},[801],{"nctId":480,"briefTitle":481,"status":61,"phases":802,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":803,"interventions":804},[42,43],[488],[459,490],{"trials":806,"activeCount":53},[],{"trials":808,"activeCount":53},[],{"intervention":810,"totalTrials":11,"cells":811},"BT",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":824,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":813,"activeCount":53},[],{"trials":815,"activeCount":53},[816],{"nctId":817,"briefTitle":818,"status":61,"phases":819,"primaryCompletion":386,"completion":719,"start":373,"enrollment":820,"conditions":821,"interventions":823},"NCT02003027","Botulinum Toxin Injection to Prevent VT Storm",[41],15,[822],"VT Storm",[810],{"trials":825,"activeCount":53},[826],{"nctId":827,"briefTitle":828,"status":61,"phases":829,"primaryCompletion":386,"completion":719,"start":373,"enrollment":406,"conditions":830,"interventions":831},"NCT02008448","Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation",[42],[408],[810],{"trials":833,"activeCount":53},[],{"trials":835,"activeCount":53},[],{"trials":837,"activeCount":53},[],{"intervention":476,"totalTrials":108,"cells":839},{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":850,"PHASE4":852,"NA":854},{"trials":841,"activeCount":53},[],{"trials":843,"activeCount":53},[],{"trials":845,"activeCount":53},[846],{"nctId":468,"briefTitle":469,"status":61,"phases":847,"primaryCompletion":405,"completion":471,"start":373,"enrollment":311,"conditions":848,"interventions":849},[42],[473,474],[459,476],{"trials":851,"activeCount":53},[],{"trials":853,"activeCount":53},[],{"trials":855,"activeCount":53},[],{"intervention":70,"totalTrials":108,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":859,"activeCount":53},[],{"trials":861,"activeCount":53},[],{"trials":863,"activeCount":53},[864],{"nctId":59,"briefTitle":60,"status":61,"phases":865,"primaryCompletion":63,"completion":64,"start":65,"enrollment":66,"conditions":866,"interventions":867},[42],[68],[70,48],{"trials":869,"activeCount":53},[],{"trials":871,"activeCount":53},[],{"trials":873,"activeCount":53},[],{"intervention":875,"totalTrials":108,"cells":876},"Botulinum Toxin Type A",{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":890,"PHASE4":892,"NA":894},{"trials":878,"activeCount":53},[],{"trials":880,"activeCount":53},[],{"trials":882,"activeCount":53},[883],{"nctId":884,"briefTitle":885,"status":61,"phases":886,"primaryCompletion":405,"completion":719,"start":373,"enrollment":66,"conditions":887,"interventions":889},"NCT02002962","Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter",[42],[888],"Atrial Flutter",[875],{"trials":891,"activeCount":53},[],{"trials":893,"activeCount":53},[],{"trials":895,"activeCount":53},[],{"intervention":897,"totalTrials":108,"cells":898},"Optimal medial therapy",{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":900,"activeCount":53},[],{"trials":902,"activeCount":53},[],{"trials":904,"activeCount":53},[905],{"nctId":906,"briefTitle":907,"status":74,"phases":908,"primaryCompletion":373,"completion":373,"start":909,"enrollment":311,"conditions":910,"interventions":912},"NCT01898910","Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation",[42],"2012-06",[15,911],"Hypertension",[897],{"trials":914,"activeCount":53},[],{"trials":916,"activeCount":53},[],{"trials":918,"activeCount":53},[],{"intervention":447,"totalTrials":108,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":925,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":922,"activeCount":53},[],{"trials":924,"activeCount":53},[],{"trials":926,"activeCount":53},[927],{"nctId":439,"briefTitle":440,"status":61,"phases":928,"primaryCompletion":85,"completion":442,"start":443,"enrollment":444,"conditions":929,"interventions":930},[42],[15,20],[447,400],{"trials":932,"activeCount":53},[],{"trials":934,"activeCount":53},[],{"trials":936,"activeCount":53},[],{"intervention":938,"totalTrials":108,"cells":939},"Anti-Arrhythmia Agents",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":941,"activeCount":53},[],{"trials":943,"activeCount":53},[],{"trials":945,"activeCount":53},[946],{"nctId":947,"briefTitle":948,"status":74,"phases":949,"primaryCompletion":670,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":955},"NCT01709682","A Comparison of the Drug Therapy Versus Re-Ablation",[42],"2012-08","2007-11",154,[25,954],"Failed First Radiofrequency Ablation Procedure",[938],{"trials":957,"activeCount":53},[],{"trials":959,"activeCount":53},[],{"trials":961,"activeCount":53},[],{"intervention":963,"totalTrials":108,"cells":964},"7.2% NaCl plus 6% hydroxyethyl starch 200\u002F0.5",{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":979,"PHASE4":981,"NA":983},{"trials":966,"activeCount":53},[],{"trials":968,"activeCount":53},[],{"trials":970,"activeCount":53},[971],{"nctId":972,"briefTitle":973,"status":74,"phases":974,"primaryCompletion":396,"completion":396,"start":670,"enrollment":249,"conditions":975,"interventions":977},"NCT01675453","The Efficacy and Safety of Hypertonic Saline in Cardiac Surgery Patients.",[42],[17,976],"Edema",[963,978],"0.9% NaCl",{"trials":980,"activeCount":53},[],{"trials":982,"activeCount":53},[],{"trials":984,"activeCount":53},[],{"intervention":978,"totalTrials":108,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":997,"PHASE4":999,"NA":1001},{"trials":988,"activeCount":53},[],{"trials":990,"activeCount":53},[],{"trials":992,"activeCount":53},[993],{"nctId":972,"briefTitle":973,"status":74,"phases":994,"primaryCompletion":396,"completion":396,"start":670,"enrollment":249,"conditions":995,"interventions":996},[42],[17,976],[963,978],{"trials":998,"activeCount":53},[],{"trials":1000,"activeCount":53},[],{"trials":1002,"activeCount":53},[],{"intervention":141,"totalTrials":108,"cells":1004},{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1006,"activeCount":53},[],{"trials":1008,"activeCount":53},[1009],{"nctId":131,"briefTitle":132,"status":61,"phases":1010,"primaryCompletion":134,"completion":134,"start":64,"enrollment":135,"conditions":1011,"interventions":1012},[41],[137,138,139],[141,124],{"trials":1014,"activeCount":53},[],{"trials":1016,"activeCount":53},[],{"trials":1018,"activeCount":53},[],{"trials":1020,"activeCount":53},[],{"intervention":1022,"totalTrials":108,"cells":1023},"Therapy: aspirin and clopidogrel",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1025,"activeCount":53},[],{"trials":1027,"activeCount":53},[1028],{"nctId":1029,"briefTitle":1030,"status":74,"phases":1031,"primaryCompletion":1032,"completion":1033,"start":1034,"enrollment":1035,"conditions":1036,"interventions":1038},"NCT02209350","Study of the AFB and Stenting of the Iliac Arteries",[41],"2020-11-01","2020-11-02","2015-08-02",202,[1037],"Aorta-iliac Segment Lesion (C,D Type by TASC II)",[1022],{"trials":1040,"activeCount":53},[],{"trials":1042,"activeCount":53},[],{"trials":1044,"activeCount":53},[],{"trials":1046,"activeCount":53},[],{"intervention":1048,"totalTrials":108,"cells":1049},"Optimal medicamentous treatment",{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1051,"activeCount":53},[],{"trials":1053,"activeCount":53},[],{"trials":1055,"activeCount":53},[],{"trials":1057,"activeCount":53},[],{"trials":1059,"activeCount":53},[],{"trials":1061,"activeCount":53},[1062],{"nctId":1063,"briefTitle":1064,"status":74,"phases":1065,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1070},"NCT02769650","Stress-MRI Assessment After Right Coronary Artery CTO Recanalization",[45],"2014-04","2010-10",72,[20,30,17,32],[1048],{"intervention":1072,"totalTrials":108,"cells":1073},"B-blockers",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1075,"activeCount":53},[],{"trials":1077,"activeCount":53},[],{"trials":1079,"activeCount":53},[],{"trials":1081,"activeCount":53},[],{"trials":1083,"activeCount":53},[],{"trials":1085,"activeCount":53},[1086],{"nctId":1087,"briefTitle":1088,"status":61,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":66,"conditions":1093,"interventions":1094},"NCT03539354","TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery",[45],"2019-05","2020-05","2018-07-01",[17,15],[1072]]